With 55721.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.27 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $8.08 whereas the lowest price it dropped to was $7.925. The 52-week range on LFCR shows that it touched its highest point at $8.63 and its lowest point at $3.68 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 0.67.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LFCR was down-trending over the past week, with a drop of -2.31%, but this was up by 17.03% over a month. Three-month performance surged to 11.67% while six-month performance rose 8.36%. The stock gained 8.21% in the past year, while it has gained 70.34% so far this year. A look at the trailing 12-month EPS for LFCR yields -1.48 with Next year EPS estimates of -0.70. For the next quarter, that number is -0.10. This implies an EPS growth rate of -515.62% for this year and 47.37% for next year.
Float and Shares Shorts:
At present, 37.03 million LFCR shares are outstanding with a float of 32.67 million shares on hand for trading. On 2025-06-13, short shares totaled 2.3 million, which was 620.0 higher than short shares on 1747267200. In addition to Mr. Paul Josephs as the firm’s President, CEO & Director, Mr. Ryan D. Lake CPA serves as its EVP & CFO.
Institutional Ownership:
Through their ownership of 0.72405 of LFCR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-02-23, LFCR reported revenue of $35154000.0 and operating income of -$2293000.0. The EBITDA in the recently reported quarter was $116000.0 and diluted EPS was -$0.47.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With LFCR analysts setting a high price target of 10.0 and a low target of 10.0, the average target price over the next 12 months is 10.0. Based on these targets, LFCR could surge 24.38% to reach the target high and rise by 24.38% to reach the target low. Reaching the average price target will result in a growth of 24.38% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.42015 being high and $0.40478 being low. For LFCR, this leads to a yearly average estimate of $0.41.
